QXW

Cryoablation Device For Local Treatment Of Low-Risk Breast Cancer

Product code
QXW
Device name
Cryoablation Device For Local Treatment Of Low-Risk Breast Cancer
Device class
Class 2
21 CFR
21 CFR 878.4355
Medical specialty
General, Plastic Surgery
Marketing pathway
510(K)
510(k) clearances (last 3 years)
1
Summaries archived here
0 (direct download)
510(k) clearances (all years, FDA)
1 (all years; only the last 3 years are listed here)

FDA classification definition

A cryoablation device for local treatment of low-risk breast cancer is a prescription device that uses cold temperatures to destroy a breast tumor and its surrounding tissue. The device is intended as a local treatment and may be used with adjuvant therapies (e.g., endocrine therapy, radiation therapy) to reduce the risk of local disease progression. The device is intended for use in patients with a well-defined solid tumor (e.g., invasive ductal carcinoma) and with low risk of recurrence and metastasis, as determined by clinical risk factors consistent with the indications for use. The device is not intended to treat breast cancers with high risk of local recurrence (e.g., lobular carcinoma), patients with aggressive forms of breast cancer (e.g., breast cancers with inflammatory features), or patients in whom targeted systemic therapy is indicated.

Definition text from the FDA device classification database (U.S. federal government work, public domain).

510(k) clearances, last 3 years (1)

Last three years. Most recent: 2025-10-03.

NumberDecision dateApplicantDevice nameSummary
DEN2200772025-10-03Icecure MedicalProSense™ System
Official FDA classification page: QXW
Classification and pathway per current FDA publications. Data from openFDA (CC0).